An upgrade to the computer-aided detection product line from R2 Technology gives users a choice of operating points to set different sensitivity/false marker rates for microcalcifications and masses in the breast. The enhanced system allows users to set sensitivity to their own comfort levels, providing unprecedented flexibility, according to the company.
An upgrade to the computer-aided detection product line from R2 Technology gives users a choice of operating points to set different sensitivity/false marker rates for microcalcifications and masses in the breast. The enhanced system allows users to set sensitivity to their own comfort levels, providing unprecedented flexibility, according to the company.
The flexible operating points feature is part of R2's new software release, ImageChecker Version 8.1 Mammography CAD, which is displayed at the RSNA meeting. This version is being made available across the company's mammography CAD product line and to its entire installed base as an upgrade.
Version 8.1 includes two other major features. The new Malc Mark identifies regions of breast tissue that contain both a mass and calcifications. EmphaSize variable size CAD marks correlate the size of a CAD mark with the potential for malignancy: Small marks reflect a lower chance of malignancy, and large marks indicate more suspicious findings.
Study: Mammography AI Leads to 29 Percent Increase in Breast Cancer Detection
February 5th 2025Use of the mammography AI software had a nearly equivalent false positive rate as unassisted radiologist interpretation and resulted in a 44 percent reduction in screen reading workload, according to findings from a randomized controlled trial involving over 105,000 women.
Can AI Bolster Breast Cancer Detection in DBT Screening?
January 16th 2025In sequential breast cancer screening with digital breast tomosynthesis (DBT), true positive examinations had more than double the AI case score of true negative examinations and the highest positive AI score changes from previous exams, according to new research.
Mammography Study Suggests DBT-Based AI May Help Reduce Disparities with Breast Cancer Screening
December 13th 2024New research suggests that AI-powered assessment of digital breast tomosynthesis (DBT) for short-term breast cancer risk may help address racial disparities with detection and shortcomings of traditional mammography in women with dense breasts.
Mammography News: FDA Grants Expanded 510(k) Clearance for AI-Powered SmartMammo Dx DBT Software
November 29th 2024Originally cleared by the FDA in 2021, the SmartMammo Dx software for digital breast tomosynthesis (DBT) can now be utilized with the Senographe Pristina mammography systems from GE HealthCare.